No evidence of increased risk for Coronavirus Disease 2019 (COVID‐19) in patients treated with Dupilumab for atopic dermatitis in a high‐epidemic area – Bergamo, Lombardy, Italy-Reference-Cited by-同舟云学术

No evidence of increased risk for Coronavirus Disease 2019 (COVID‐19) in patients treated with Dupilumab for atopic dermatitis in a high‐epidemic area – Bergamo, Lombardy, Italy

Published:2020-06-15 Issue:9 Volume:34 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Carugno A.¹^ORCID,Raponi F.¹,Locatelli A.G.¹,Vezzoli P.¹,Gambini D.M.¹,Di Mercurio M.¹,Robustelli Test E.²,Sena P.¹

Affiliation:

1. Dermatology Unit ASST Papa Giovanni XXIII Hospital Bergamo Italy

2. Dermatology Clinic Department of Medical Sciences and Public Health University of Cagliari Cagliari Italy

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.16552

Reference10 articles.

1. Dupilumab: A review of its use in the treatment of atopic dermatitis

2. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis

3. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy

4. Papa Giovanni XXIII Bergamo Hospital at the time of the COVID‐19 outbreak: Letter from the warfront…

5. Cutaneous manifestations in COVID‐19: a first perspective

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review;Journal of Allergy and Clinical Immunology: Global;2024-02

2. Atopic Dermatitis;Advanced Emergency Nursing Journal;2023-07

3. The impact of chronic rhinosinusitis on COVID-19 risk and outcomes: A systematic review and meta-analysis;Frontiers in Immunology;2023-03-29

4. Dupilumab for Atopic Dermatitis—From Clinical Trials to Molecular and Cellular Mechanisms;Dermatitis®;2023-02-01

5. The effects of systemic immunomodulatory treatments on COVID ‐19 outcomes in patients with atopic dermatitis: Results from the global SECURE‐AD registry;Journal of the European Academy of Dermatology and Venereology;2022-10-12